Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus May Boost Policy Efforts To Enhance US Drug, Medical Supply Production

Executive Summary

Sen. Alexander says Congress should consider options to alleviate US dependence on other countries for drug and medical supply production once the outbreak subsides.

You may also be interested in...



Acyclovir Availability In US May Be Affected By India Export Restrictions

USP information suggests many firms in India, which is restricting exports of the antibiotic, as well as China, produce it for the US market.

CureVac’s German Owner Rejects US Coronavirus Vaccine Grab

Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.

India Export Restrictions: Balancing Tweaks In Store?

Some transitional arrangements may help Indian drug firms process export obligations already underway prior to recent government restrictions designed to safeguard domestic supplies against the backdrop of supply chain stress due to the coronavirus outbreak. But will the Indian government tweak the restrictions to balance home demands and exports?

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141778

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel